Bortezomib plus melphalan and prednisole in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study Marı´a-Victoria Mateos, Jose´-M. Herna´ndez, Miguel-T. Herna´ndez,Norma-C. Gutie´ rrez, Luis Palomera, Marta Fuertes, Joaquı´n Dı´az-Mediavilla, Juan-J. Lahuerta, Javier de la Rubia Marı´a- Jose´ Terol BLOOD October Vol. 108

Introduction   Multiple myeloma : a malignant proliferation of plasma cells derived from a single clone.  Standard care of MM has been MP.  HDT with ASCT is now considered standard therapy for younger patients.  BORTEZOMIB : the first proteasome inhibitor to enter the clinic. the first proteasome inhibitor to enter the clinic. a reversible inhibitor of the 26S proteasome. a reversible inhibitor of the 26S proteasome. an enzyme involved in the catabolic pathway fo numerous intracellular regulatory proteins. an enzyme involved in the catabolic pathway fo numerous intracellular regulatory proteins.

Patients and methods  Study design :  Study design : open-label, phase 1/2, dose-escalation study was carried out at 19centers in Spain  PATIENTS :  PATIENTS : newly diagnosed symptomatic MM with measurable disease, age of at least 65 years, Karnofsky performance status (KPS) of at least 60%, and a life expectancy of more than 3 months  VMP schedule

Results

Fig 2. Response to VMP was rapid

Fig 3. Time to events data in patients receiving VMP

Figure 4. Influence of cytogenetic abnormalities on PFS and EFS..

  VMP is a more effective first-line regimen than MP in patients not eligible for transplantation, Discussion